Peregrine Cancer Drug Shows Promise in Midstage Study

Peregrine Pharmaceuticals Inc said its experimental drug for the treatment of lung cancer met the main goal in the first phase of a mid-stage study, sending its shares up 23 percent before the bell.
CNBC